Cardior Overview
- Year Founded
-
2016
- Status
-
Acquired/Merged
- Employees
-
35
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$1.12B
Cardior General Information
Description
Operator of a biopharmaceutical platform intended to focus on the discovery, development and clinical validation of non-coding RNA therapeutics. The company's platform provides a novel class of therapeutics and a revolutionary approach to prevent, repair and reverse diseases of the heart and uses distinctive non-coding RNAs to address the root causes of cardiac dysfunctions, enabling patients to lead healthy and strong lives.
Contact Information
Website
www.cardior.de(Operating Subsidiary)
Corporate Office
- Hollerithallee 20
- 30419 Hannover
- Germany
Corporate Office
- Hollerithallee 20
- 30419 Hannover
- Germany
Cardior Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Merger/Acquisition | 25-Mar-2024 | $1.12B | Completed | Clinical Trials - Phase 2 | ||
| 7. Accelerator/Incubator | Completed | Clinical Trials - Phase 2 | ||||
| 6. Later Stage VC (Series B) | 25-Aug-2021 | Completed | Clinical Trials - Phase 2 | |||
| 5. Early Stage VC | Completed | Clinical Trials - Phase 2 | ||||
| 4. Grant | 11-Dec-2018 | Completed | Clinical Trials - Phase 2 | |||
| 3. Early Stage VC (Series A) | 11-May-2017 | Completed | Clinical Trials - Phase 2 | |||
| 2. Accelerator/Incubator | 06-Apr-2017 | $108K | Completed | Clinical Trials - Phase 2 | ||
| 1. Accelerator/Incubator | $108K | $108K | Completed | Startup |
Cardior Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Ordinary |
Cardior Comparisons
Industry
Financing
Details
Cardior Competitors (68)
One of Cardior’s 68 competitors is Cardurion, a Venture Capital-Backed company based in Burlington, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Cardurion | Venture Capital-Backed | Burlington, MA | ||||
| Nanoviricides | Corporation | Shelton, CT | ||||
| Anavex Life Sciences | Corporation | New York, NY | ||||
| Apellis Pharmaceuticals | Formerly VC-backed | Waltham, MA | ||||
| Metcela | Venture Capital-Backed | Kawasaki, Japan |
Cardior Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Cardior Patents
Cardior Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3143100-A1 | Treatment of heart failure in human subjects | Active | 14-Jun-2019 | ||
| WO-2020249713-A1 | Treatment of heart failure in human subjects | Inactive | 14-Jun-2019 | ||
| US-20120180147-A1 | Microrna-24 | Active | 16-Jul-2009 | ||
| US-8691783-B2 | Microrna-24 | Inactive | 16-Jul-2009 | ||
| US-20100010073-A1 | Microrna (mirna) for the diagnosis and treatment of heart diseases | Active | 09-Oct-2006 | C12Q1/6883 |
Cardior Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Cardior Former Investors (14)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Ascenion | Accelerator/Incubator | |||
| BioMedPartners | Venture Capital | Minority | ||
| Boehringer Ingelheim Venture Fund | Corporate Venture Capital | Minority | ||
| Bristol-Myers Squibb | Corporation | Minority | ||
| Coparion | Venture Capital | Minority |
Cardior Investments (1)
Cardior’s most recent deal was a Corporate Asset Purchase with Bayerische Patentallianz (Four MicroRNA Patents). The deal was made on 01-Nov-2018.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Bayerische Patentallianz (Four MicroRNA Patents) | 01-Nov-2018 | Corporate Asset Purchase | Buildings and Property |
Cardior FAQs
-
When was Cardior founded?
Cardior was founded in 2016.
-
Where is Cardior headquartered?
Cardior is headquartered in Hannover, Germany.
-
What is the size of Cardior?
Cardior has 35 total employees.
-
What industry is Cardior in?
Cardior’s primary industry is Drug Discovery.
-
Is Cardior a private or public company?
Cardior is a Private company.
-
What is the current valuation of Cardior?
The current valuation of Cardior is .
-
What is Cardior’s current revenue?
The current revenue for Cardior is .
-
How much funding has Cardior raised over time?
Cardior has raised $102M.
-
Who are Cardior’s investors?
Ascenion, BioMedPartners, Boehringer Ingelheim Venture Fund, Bristol-Myers Squibb, and Coparion are 5 of 14 investors who have invested in Cardior.
-
Who are Cardior’s competitors?
Cardurion, Nanoviricides, Anavex Life Sciences, Apellis Pharmaceuticals, and Metcela are some of the 68 competitors of Cardior.
-
When was Cardior acquired?
Cardior was acquired on 25-Mar-2024.
-
Who acquired Cardior?
Cardior was acquired by Novo Nordisk.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
